---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040317"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:13:14.215362+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Celcuity Q3 net loss $18.4M; raises $50M; advances gedatolisib in prostate cancer

## Summary
- Q3 net loss $18.4M ($0.83 loss per share) vs $10.9M ($0.75) YoY; non-GAAP adjusted loss $17.3M ($0.78).
- Closed $50M private placement equity in October 2023; cash runway extended into mid-2026.
- FDA cleared IND for gedatolisib + darolutamide in mCRPC; entered Bayer supply agreement for darolutamide.
- VIKTORIA-1 Phase 3 (HR+/HER2- breast cancer) on track: PIK3CA wt data H2 2024, PIK3CA mut data H1 2025.
- CELC-G-201 Phase 1b/2 (mCRPC) site activation Q1 2024; initial data expected H1 2025.

## SEC filing metadata
- accession: 0001493152-23-040317
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000149315223040317/0001493152-23-040317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000149315223040317/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040317
- JSON: https://secwatch.observer/filing/0001493152-23-040317.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040317.txt

## Key facts
- Earnings Releases
  Celcuity Inc. reported the third quarter ended September 30, 2023 results: net income $18.4 million, EPS $0.83 loss per share.
  - Period: the third quarter ended September 30, 2023
  - Net income: $18.4 million
  - EPS: $0.83 loss per share
  - Result: reported results
  source text: Net loss for the third quarter of 2023 was $18.4 million, or $0.83 loss per share, compared to a net loss of $10.9 million, or $0.75 loss per share, for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1603454/000149315223040317/0001493152-23-040317-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.